Jan 13 (Reuters) - Johnson & Johnson JNJ.N said on Monday it would buy drugmaker Intra-Cellular Therapies ITCI.O for $14.6 billion, boosting its presence in the market for neurological disorder treatments.
(Reporting by Puyaan Singh and Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.